Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
暂无分享,去创建一个
D. Hose | H. Goldschmidt | A. Jauch | T. Hielscher | I. Schmidt-Wolf | M. Merz | A. Seckinger | C. Scheid | K. Neben | U. Bertsch | J. Hillengass | H. Salwender | M. Raab | E. Mai | K. Weisel | M. Haenel | I. Blau | H. Lindemann
[1] D. Landau,et al. Genomic complexity of multiple myeloma and its clinical implications , 2017, Nature Reviews Clinical Oncology.
[2] S. Lonial,et al. Integration of Novel Agents into the Care of Patients with Multiple Myeloma , 2016, Clinical Cancer Research.
[3] S. Rajkumar,et al. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma , 2016, Clinical Cancer Research.
[4] Erich A. Peterson,et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. , 2016, Blood.
[5] D. Dingli,et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents , 2016, Leukemia.
[6] H. Goldschmidt,et al. Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. , 2016, Blood.
[7] D. Dingli,et al. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma , 2016, Leukemia.
[8] D. Hose,et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma , 2016, Haematologica.
[9] M. Mohty,et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? , 2015, Blood.
[10] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Ru,et al. The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma , 2015, Clinical Cancer Research.
[12] H. Goldschmidt,et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] T. Chevassut,et al. The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.
[14] D. Hose,et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Moreau,et al. The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma , 2013, Clinical Cancer Research.
[16] B. Barlogie,et al. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. , 2013, Blood.
[17] G. Morgan,et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. , 2013, Blood.
[18] M. Kersten,et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Hose,et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. , 2012, Blood.
[20] A. Dispenzieri,et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma , 2011, Leukemia.
[21] Axel Benner,et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma , 2011, Haematologica.
[22] V. Peng,et al. A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide , 2010, Leukemia.
[23] B. Barlogie,et al. Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q , 2005, Genes, chromosomes & cancer.
[24] P. L. Bergsagel,et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[25] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.